Łukasz Chętko

Dr. Łukasz Chętko

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMMaria Markowska
Maria Markowska
ŁCŁukasz Chętko
Łukasz Chętko
NBNatalia Bień
Natalia Bień
MRMaria Rajczak
Maria Rajczak
MCMagdalena Ciazynska
Magdalena Ciazynska
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Background: Primary cutaneous B-cell lymphomas (CBCLs) are a rare and heterogeneous group of lymphomas, among which the anaplastic variant of diffuse large B-cell lymphoma (A-DLBCL) represents an exceptionally rare entity. Although they typically present as painless and non-ulcerated skin lesions, rare variants may exhibit atypical clinical features. Pyoderma gangrenosum (PG) is a rare inflammatory ulcerative disease that may overlap clinically with other ulcerative dermatoses and pose diagnostic challenges due to the absence of standardized differential algorithms. Methods: An 85-year-old male presented with multiple rapidly progressive, painful, ulcerative lesions, initially misdiagnosed as PG and treated with oral cyclosporine with no clinical response. Skin biopsy specimens underwent detailed histopathological and immunohistochemical evaluation. Results: The analyses revealed dense infiltration of atypical large lymphoid cells, with CD20, CD45, and CD30 positivity, and a Ki-67 proliferation index of approximately 90%, consistent with primary cutaneous A-DLBCL. Owing to the delayed correct diagnosis, the patient’s condition deteriorated rapidly, leading to his death before appropriate therapy could be initiated. Conclusions: The case documents an exceptionally rare cutaneous presentation of A-DLBCL, expanding the extremely limited literature on this enigmatic entity. Furthermore, it underscores the fundamental role of early skin biopsy in the differential diagnosis of non-specific ulcerative lesions, which is critical for ensuring appropriate treatment administration within the therapeutic window in cases of malignancy.

30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAleksandra Serafin
Aleksandra Serafin
ASAleksandra Suchołbiak
Aleksandra Suchołbiak
KBKarolina Baran
Karolina Baran
MPMaja Podolak
Maja Podolak
KPKlaudia Pachulska
Klaudia Pachulska
ŁCŁukasz Chętko
Łukasz Chętko
Introduction: Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor of low-to-intermediate malignant potential with an incompletely defined biological behaviour, exhibiting both benign and malignant features. It most commonly affects the liver, but may also involve other organs, such as the lungs and bones. Due to its heterogeneous clinical presentation and similarity to other vascular tumors primarily affecting the liver, misdiagnosis remains a common clinical challenge. Currently, several therapeutic approaches are used depending on various factors, but liver transplantation (LTx) is increasingly considered as the treatment option for patients with metastatic HEHE, particularly in unresectable cases. Several studies indicate a favorable prognosis following transplantation for HEHE. Aim of the Study: The aim of this study is to review the existing literature on treatment outcomes and to identify prognostic factors in patients undergoing LTx due to HEHE. Materials and Methods: A comprehensive literature review was performed using the PubMed database. Results and Conclusions: LTx is a crucial treatment option for patients with unresectable and multifocal HEHE. Current data indicate that post-transplant survival rates are favorable, with the potential to achieve durable, recurrence-free survival - even in the presence of extrahepatic metastases. Several prognostic factors have been identified that may influence post-transplant outcomes, including tumor burden, presence of extrahepatic disease (EHD), vascular invasion and tumor growth dynamics. In light of the limited efficacy of available systemic therapies, LTx should be considered the preferred treatment option in carefully selected patients with advanced HEHE. Nevertheless, long-term follow-up remains crucial to identify potential recurrence or complications.

24 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JHJulia Hofmann
Julia Hofmann
ŁCŁukasz Chętko
Łukasz Chętko
IBIgor Bednarski
Igor Bednarski
MRMaria Rajczak
Maria Rajczak
MDMałgorzata Dominiak
Małgorzata Dominiak
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Background/Objectives: Alopecia areata (AA) is a widespread autoimmune condition causing non-scarring hair loss, significantly affecting the quality of life. Despite its prevalence, data on diagnostic and treatment efficacy and the quality of patients’ care in Poland remain unstudied. The aim of this study was to assess the current clinical approaches to the diagnosis and management of alopecia areata by dermatologists in Poland and to highlight the challenges encountered by Polish patients. Methods: A cross-sectional study was conducted regarding dermatologists and AA patients in Po-land. The data were gathered from distinct proprietary surveys: an original questionnaire for doctors, and DLQI, CDLQI, AAPPO, WPAI+CIQ:AS, and SF-36 questionnaires for patients. Results: The study included 100 dermatologists and 252 pa-tients from Poland. The study revealed that the care provided to patients with alopecia areata is inadequate and lacks a comprehensive approach, despite the negative disease impact on patients’ quality of life. A number of physicians do not follow the diagnostic and treatment guidelines. Despite the registration of next-generation treatments like Janus kinase inhibitors, access to these medications remained limited until recently. Conclusions: Alopecia areata in Poland poses significant diagnostic, therapeutic, and psychosocial challenges. While clinical practice largely aligns with international recommendations, notable gaps remain in the use of validated severity tools, psychosocial assessment, and access to advanced therapies. The recent reimbursement of ritlecitinib represents a breakthrough, bringing Polish care in line with global stand-ards. However, optimal management requires not only pharmacological advances but also interdisciplinary strategies integrating psychological support, patient advocacy, and public education to reduce stigma and improve overall quality of life for affected individuals.

1 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JHJulia Hofmann
Julia Hofmann
ŁCŁukasz Chętko
Łukasz Chętko
IBIgor Bednarski
Igor Bednarski
MRMaria Rajczak
Maria Rajczak
MDMałgorzata Dominiak
Małgorzata Dominiak
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Objectives: Alopecia areata (AA) is a widespread autoimmune condition causing non-scarring hair loss, significantly affecting the quality of life. Despite its prevalence, data on diagnostic and treatment efficacy and the quality of patient care in Poland remain unstudied. The aim of this study was to assess the current clinical approaches to the diagnosis and management of alopecia areata by dermatologists in Poland and to highlight the challenges encountered by Polish patients. Methods: A cross-sectional study was conducted regarding dermatologists and AA patients in Poland. The data were gathered from distinct proprietary surveys: an original questionnaire for doctors, and DLQI, CDLQI, AAPPO, WPAI+CIQ:AS, and SF-36 questionnaires for patients. Results: The study included 100 dermatologists and 252 patients from Poland. The study revealed that the care provided to patients with alopecia areata is inadequate and lacks a comprehensive approach, despite the negative disease impact on patients’ quality of life. A number of physicians do not follow the diagnostic and treatment guidelines. Despite the registration of next-generation treatments like Janus kinase inhibitors, access to these medications remained limited until recently. Conclusions: Alopecia areata in Poland poses significant diagnostic, therapeutic, and psychosocial challenges. While clinical practice largely aligns with international recommendations, notable gaps remain in the use of validated severity tools, psychosocial assessment, and access to advanced therapies. The recent reimbursement of ritlecitinib represents a breakthrough, bringing Polish care in line with global standards. However, optimal management requires not only pharmacological advances but also interdisciplinary strategies integrating psychological support, patient advocacy, and public education to reduce stigma and improve overall quality of life for affected individuals.

Verified
Journal Article
Open access
PDF file
ŁCŁukasz Chętko
Łukasz Chętko
JHJulia Hofmann
Julia Hofmann
KBKarolina Brzychcy
Karolina Brzychcy
MMMarta Matych
Marta Matych
DSDorota Sobolewska-Sztychny
Dorota Sobolewska-Sztychny
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Background: Alopecia areata (AA) is an autoimmune disease characterized by diverse patterns of non-scarring hair loss. Due to its susceptibility to immune dysregulation and psychological stress, there is growing speculation regarding the potential role of SARS-CoV-2 infection and the COVID-19 pandemic in its development, recurrence, or exacerbation. This retrospective study aimed to evaluate patients affected by AA from a single dermatological center, specifically focusing on the impact of the COVID-19 pandemic on hospitalization rates. Methods: Data comprising demographic characteristics, disease subtype, number, and duration of hospitalizations were digitized and statistically analyzed. The five-year period prior to the pandemic (2015–2019) was compared with the subsequent four years (2020–2023) to assess any changes. Results: The study involved 428 individuals (256 children and 172 adults), with a slight predominance of women (68.2%). The median ages in adults and children were 39.13 years and 8.66 years, respectively. Following the pandemic, there was a 13.81% decrease in the mean age among adult males. Hospitalizations surged by 207.62% after the pandemic, increasing from 223 to 686 admissions. Additionally, the diagnosis of alopecia areata totalis increased significantly by 55.6%. The residential distribution of pediatric patients also shifted notably, with 72.16% residing in urban areas and 27.84% in rural areas between 2020 and 2023. Conclusions: The significant increase in hospitalization rates and the diversity of disease subtypes observed in this study may suggest a potential correlation between COVID-19 and the development or altered course of alopecia areata. A deeper understanding of this association could enhance treatment outcomes in dermatology, ultimately improving patient care.

4 November 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
NBNatalia Bień
Natalia Bień
TPThomas Peric
Thomas Peric
ŁCŁukasz Chętko
Łukasz Chętko
MRMaria Rajczak
Maria Rajczak
JNJoanna Narbutt
Joanna Narbutt
ALAleksandra Lesiak
Aleksandra Lesiak
Background: Dystrophic epidermolysis bullosa (DEB) is a rare genetic disorder associated with substantial and multidimensional disease burden. Although therapeutic options are advancing globally, patients in Central and Eastern Europe continue to face significant systemic barriers, including limited access to specialized care and innovative treatments. This study aimed to comprehensively assess health-related quality of life (HRQoL) and symptom burden in a national cohort of patients with DEB in Poland, with the objective of identifying key unmet needs. Methods: A cross-sectional study was conducted in collaboration with the EB Polska Foundation. Data were collected through a structured, multi-modular online survey. Symptom severity, including pain and pruritus, was evaluated using an 11-point Numeric Rating Scale (NRS). HRQoL was assessed using validated dermatology-specific instruments (DLQI/CDLQI, Skindex-29) alongside a generic measure (SF-36). Statistical analysis was limited to descriptive methods. Results: A total of 33 patients with DEB were included (mean age: 23.7 years; 75.8% female). The cohort exhibited a high symptom burden, with mean NRS scores of 5.7 for pain and 5.9 for pruritus. Dermatology-specific instruments indicated severe impairment in HRQoL (mean DLQI: 13.9; CDLQI: 14.3), with the highest burden observed in the symptoms domain of Skindex-29 (mean: 48.9). In contrast, the SF-36 revealed a marked discrepancy between physical and mental health domains: physical functioning remained relatively preserved (mean: 94.5), whereas mental health scores were markedly reduced (mean: 22.4), indicating substantial psychological morbidity. Conclusions: Patients with DEB in Poland experience a considerable symptom burden and pronounced psychological distress, despite maintaining relatively preserved physical functioning, potentially reflecting adaptive coping mechanisms. This discordance highlights persistent disparities in care. Addressing these gaps requires systemic healthcare interventions, including the development of specialized reference centers for rare diseases, integration of routine psychological assessment, and improved access to disease-modifying therapies.